Written Question·Department for Science, Innovation and Technology·UIN 18585

Innovation and Technology: Obesity

Tabled: 14 July 2026

Answered: 20 July 2026

Question

Esther McVey

To ask the Secretary of State for Science, Innovation and Technology, pursuant to the Answer of 13 July 2026 to Question 15321 on Innovation and Technology: Obesity, whether the evaluation activity will be independent of Eli Lilly and Company; whether it

Answer

Kanishka Narayan

The Obesity Pathway Innovation Programme evaluation has been commissioned independently through the National Institute for Health and Care Research and is entirely independent of Eli Lilly and Company. The evaluation team is currently working with funded ...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 18585) →